
I hereby certify that this correspondence is being Commissioner to Patents Washington, D.C. 202



nereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: ommissioner to Patents Washington, D.C. 20231 on this 11the day of December 2002.

RADEMARY (Signature of Sers

(Typed or printed name of person)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SETH H. JACO

IN RE APPLICATION OF: S. McLean et al.

APPLICATION SERIAL NO.: 09/901,362 : Examiner: Vickie Kim

FILING DATE: July 9, 2001 : Group Art Unit: 1614

TITLE: Use Of Delta Opioid Receptor Ligands And:

Serotonin Reuptake Inhibitors In The

Treatment Of Chemical Dependencies

Commissioner for Patents Washington, D.C. 20231

Sir:

## RESPONSE TO RESTRICTION REQUIREMENT

This paper is in response to the Office Action of September 10, 2002. A petition for extension of time of three months is intended to be enclosed with this paper. In the event that one is not, applicants hereby make such petition and authorize the office to charge deposit account 16-1445 the required amount, or any amount required for additional extension of time.

Applicants elect the claims of group I for examination.

The Examiner has required election of a species that is disclosed. Applicants elect examination of sertraline as the serotonin reuptake inhibitor used in the method. It is noted that specific compounds are not named in the specification for the opioid receptor ligand. Applicants elect examination of the receptor ligands of formula I in the method.

Date:	_

Respectfully submitted,

Seth H. Jacobs Attorney for Applicant(s) Reg. No. 32,120

Pfizer, Inc Patent Department, 20th Floor 150 East 42nd Street New York, NY 10017-5755 (212) 733-3678